Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfredi Rizzo

Showing results (1-10 of 522) with videos related to

Pageof 53
Sort By:
Current Medicinal Chemistry|September 19, 2023
The Importance of a Novel Syndemic Approach for Cardiometabolic DiseasesManfredi Rizzo
International Journal of Molecular Sciences|December 24, 2021
Molecular Endocrinology and Metabolism in 2021: What's NewManfredi Rizzo
Current Pharmaceutical Design|February 21, 2023
Lipid Guidelines and Cardiovascular Prevention: Let's Manage the Risk of Our Patients!Manfredi Rizzo
Idrugs : the Investigational Drugs Journal|February 4, 2010
Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemiaManfredi Rizzo
Current Pharmaceutical Design|September 16, 2021
Cardiovascular and Cardioprotective Agents in 2021Manfredi Rizzo
Journal of Atherosclerosis and Thrombosis|October 6, 2005
Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?Manfredi Rizzo, Kaspar Berneis
Southern Medical Journal|September 29, 2006
Effect of statins on low-density lipoprotein size: a new role in cardiovascular prevention?Manfredi Rizzo, Kasper Berneis
Future Cardiology|October 7, 2009
Update on the role of the atherogenic lipoprotein phenotype in cardiovascular preventionManfredi Rizzo, Kaspar Berneis
Recent Patents on Cardiovascular Drug Discovery|January 29, 2008
An update on the role of the quality of LDL in cardiovascular risk: the contribution of the universities of Palermo and ZurichManfredi Rizzo, Kaspar Berneis
Current Medical Research and Opinion|May 24, 2007
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibratesManfredi Rizzo, Kaspar Berneis
Pageof 53

Showing results (1-10 of 522) with videos related to

Sort By:
Pageof 53
Current Medicinal Chemistry|September 19, 2023
The Importance of a Novel Syndemic Approach for Cardiometabolic DiseasesManfredi Rizzo
International Journal of Molecular Sciences|December 24, 2021
Molecular Endocrinology and Metabolism in 2021: What's NewManfredi Rizzo
Current Pharmaceutical Design|February 21, 2023
Lipid Guidelines and Cardiovascular Prevention: Let's Manage the Risk of Our Patients!Manfredi Rizzo
Idrugs : the Investigational Drugs Journal|February 4, 2010
Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemiaManfredi Rizzo
Current Pharmaceutical Design|September 16, 2021
Cardiovascular and Cardioprotective Agents in 2021Manfredi Rizzo
Journal of Atherosclerosis and Thrombosis|October 6, 2005
Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?Manfredi Rizzo, Kaspar Berneis
Southern Medical Journal|September 29, 2006
Effect of statins on low-density lipoprotein size: a new role in cardiovascular prevention?Manfredi Rizzo, Kasper Berneis
Future Cardiology|October 7, 2009
Update on the role of the atherogenic lipoprotein phenotype in cardiovascular preventionManfredi Rizzo, Kaspar Berneis
Recent Patents on Cardiovascular Drug Discovery|January 29, 2008
An update on the role of the quality of LDL in cardiovascular risk: the contribution of the universities of Palermo and ZurichManfredi Rizzo, Kaspar Berneis
Current Medical Research and Opinion|May 24, 2007
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibratesManfredi Rizzo, Kaspar Berneis
Pageof 53